A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Inclusion Criteria:

• Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
• Have venous access sufficient to allow for blood sampling
• Are able to swallow oral medication

Exclusion Criteria:

• Have any other skin conditions, excluding plaque psoriasis
• Have a current or recent acute, active infection
• Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
• Are lactating or breastfeeding women